Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maveropepimut S - BioVaxys

Next Previous
X
Search
Drug Profile

Maveropepimut S - BioVaxys

Alternative Names: DPX-Survivac; EMD-640744; Maveropepimut-S; MVP-S; Survivac

Latest Information Update: 28 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Serono
  • Developer IMV; Incyte Corporation; Merck Serono; Merck Sharp & Dohme; Providence Cancer Center; Sunnybrook Health Sciences Centre; University of Rome
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer; Diffuse large B cell lymphoma; Fallopian tube cancer; Glioblastoma; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Urogenital cancer
  • Phase I/II B-cell lymphoma
  • No development reported Breast cancer

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Early-stage disease, Neoadjuvant therapy) in USA (SC)
  • 03 Apr 2024 BioVaxys receives patent allowance for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX™ in USA
  • 05 Mar 2024 BioVaxys has patent pending for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX™ in European Union

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top